Abstract
Transforming growth factor β (TGF-β) is a secreted pleiotropic cytokine that is involved in a wide range of biological processes and has essential roles in development and tissue homeostasis. TGF-β elicits cellular effects by activating serine/threonine kinase receptors located at the plasma membrane and intracellular Smad effector proteins. TGF-β is an important (cardio)vascular regulator as shown by many in vitro studies on cultured endothelial and mural cells, in vivo studies in animal models, and genetic studies in which mutations in human TGF-β signaling components have been causally linked to cardiovascular diseases. Here we review recent progress in our understanding of the (dys)function of TGF-β in the cardiovascular system.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abdalla SA, Letarte M (2006) Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 43:97–110. doi:10.1136/jmg.2005.030833
Aisagbonhi O, Rai M, Ryzhov S et al (2011) Experimental myocardial infarction triggers canonical Wnt signaling and endothelial-to-mesenchymal transition. Dis Model Mech 4:469–483. doi:10.1242/dmm.006510
Akhurst RJ, Lehnert SA, Faissner A, Duffie E (1990) TGF-β in murine morphogenetic processes: the early embryo and cardiogenesis. Development 108:645–656
Anderton MJ, Mellor HR, Bell A et al (2011) Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol Pathol 39:916–924. doi:10.1177/0192623311416259
Armulik A, Abramsson A, Betsholtz C (2005) Endothelial/pericyte interactions. Circ Res 97:512–523. doi:10.1161/01.RES.0000182903.16652.d7
Armulik A, Genové G, Betsholtz C (2011) Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 21:193–215. doi:10.1016/j.devcel.2011.07.001
Arthur HM, Ure J, Smith AJ et al (2000) Endoglin, an ancillary TGF-β receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 217:42–53. doi:10.1006/dbio.1999.9534
Azhar M, Brown K, Gard C et al (2011) Transforming growth factor β2 is required for valve remodeling during heart development. Dev Dyn 240:2127–2141. doi:10.1002/dvdy.22702
Bartram U, Molin DG, Wisse LJ et al (2001) Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-β(2)-knockout mice. Circulation 103:2745–2752. doi:10.1161/01.CIR.103.22.2745
Beltrami CA, Finato N, Rocco M et al (1994) Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 89:151–163. doi:10.1161/01.CIR.89.1.151
Birukova AA, Adyshev D, Gorshkov B et al (2005) ALK5 and Smad4 are involved in TGF-β1-induced pulmonary endothelial permeability. FEBS Lett 579:4031–4037. doi:10.1016/j.febslet.2005.06.018
Blanco FJ, Santibanez JF, Guerrero-Esteo M et al (2005) Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-β receptor complex. J Cell Physiol 204:574–584. doi:10.1002/jcp.20311
Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor β in human disease. N Engl J Med 342:1350–1358. doi:10.1056/NEJM200005043421807
Bobik A (2006) Transforming growth factor-βs and vascular disorders. Arterioscler Thromb Vasc Biol 26:1712–1720. doi:10.1161/01.ATV.0000225287.20034.2c
Bobik A, Agrotis A, Kanellakis P et al (1999) Distinct patterns of transforming growth factor-β isoform and receptor expression in human atherosclerotic lesions. Colocalization implicates TGF-β in fibrofatty lesion development. Circulation 99:2883–2891. doi:10.1161/01.CIR.99.22.2883
Bolar N, Van Laer L, Loeys BL (2012) Marfan syndrome: from gene to therapy. Curr Opin Pediatr 24:498–504. doi:10.1097/MOP.0b013e3283557d4c
Bonyadi M, Rusholme SA, Cousins FM et al (1997) Mapping of a major genetic modifier of embryonic lethality in TGF-β1 knockout mice. Nat Genet 15:207–211. doi:10.1038/ng0297-207
Bot PTG, Hoefer IE, Sluijter JPG et al (2009) Increased expression of the transforming growth factor-β signaling pathway, endoglin, and early growth response-1 in stable plaques. Stroke 40:439–447. doi:10.1161/STROKEAHA.108.522284
Bourdeau A, Dumont DJ, Letarte M (1999) A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 104:1343–1351. doi:10.1172/JCI8088
Bourdeau A, Faughnan ME, McDonald ML et al (2001) Potential role of modifier genes influencing transforming growth factor-β1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am J Pathol 158:2011–2020. doi:10.1016/S0002-9440(10)64673-1
Boyer AS, Erickson CP, Runyan RB (1999) Epithelial-mesenchymal transformation in the embryonic heart is mediated through distinct pertussis toxin-sensitive and TGF-β signal transduction mechanisms. Dev Dyn 214:81–91. doi:10.1002/(SICI)1097-0177(199901)214:1<81::AID-DVDY8>3.0.CO;2-3
Brooks WW, Conrad CH (2000) Myocardial fibrosis in transforming growth factor β(1)heterozygous mice. J Mol Cell Cardiol 32:187–195. doi:10.1006/jmcc.1999.1065
Camenisch TD, Molin DGM, Person A et al (2002) Temporal and distinct TGF-β ligand requirements during mouse and avian endocardial cushion morphogenesis. Dev Biol 248:170–181. doi:10.1006/dbio.2002.0731
Cano A, Pérez-Moreno MA, Rodrigo I et al (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2:76–83. doi:10.1038/35000025
Carvalho RLC, Jonker L, Goumans M-J et al (2004) Defective paracrine signalling by TGF-β in yolk sac vasculature of endoglin mutant mice: a paradigm for hereditary haemorrhagic telangiectasia. Development 131:6237–6247. doi:10.1242/dev.01529
Chaudhry SS, Cain SA, Morgan A et al (2007) Fibrillin-1 regulates the bioavailability of TGF-β1. J Cell Biol 176:355–367. doi:10.1083/jcb.200608167
Cheifetz S, Hernandez H, Laiho M et al (1990) Distinct transforming growth factor-β (TGF-β) receptor subsets as determinants of cellular responsiveness to three TGF-β isoforms. J Biol Chem 265:20533–20538
Cheifetz S, Bellón T, Calés C et al (1992) Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 267:19027–19030
Chuva de Sousa Lopes SM, Feijen A, Korving J et al (2004) Connective tissue growth factor expression and Smad signaling during mouse heart development and myocardial infarction. Dev Dyn 231:542–550. doi:10.1002/dvdy.20162
Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 35:569–582. doi:10.1016/S0735-1097(99)00630-0
Compton LA, Potash DA, Brown CB, Barnett JV (2007) Coronary vessel development is dependent on the type III transforming growth factor β receptor. Circ Res 101:784–791. doi:10.1161/CIRCRESAHA.107.152082
Conley BA, Smith JD, Guerrero-Esteo M et al (2000) Endoglin, a TGF-β receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis 153:323–335. doi:10.1016/S0021-9150(00)00422-6
Connelly KA, Kelly DJ, Zhang Y et al (2009) Inhibition of protein kinase C-β by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail 2:129–137. doi:10.1161/CIRCHEARTFAILURE.108.765750
Creemers EE, Pinto YM (2011) Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 89:265–272. doi:10.1093/cvr/cvq308
Cruz-Gonzalez I, Pabón P, Rodríguez-Barbero A et al (2008) Identification of serum endoglin as a novel prognostic marker after acute myocardial infarction. J Cell Mol Med 12:955–961. doi:10.1111/j.1582-4934.2008.00156.x
Dağdeviren A, Müftüoğlu SF, Nur Çakar A, Örs Ü (1998) Endoglin (CD 105) expression in human lymphoid organs and placenta. Ann Anat 180:461–469. doi:10.1016/S0940-9602(98)80109-X
David L, Mallet C, Mazerbourg S et al (2007) Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109:1953–1961. doi:10.1182/blood-2006-07-034124
Dickson MC, Martin JS, Cousins FM et al (1995) Defective haematopoiesis and vasculogenesis in transforming growth factor-β 1 knock out mice. Development 121:1845–1854
Dietz HC, Cutting GR, Pyeritz RE et al (1991) Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352:337–339. doi:10.1038/352337a0
Ding R, Darland DC, Parmacek MS, D’Amore PA (2004) Endothelial–mesenchymal interactions in vitro reveal molecular mechanisms of smooth muscle/pericyte differentiation. Stem Cells Dev 13:509–520. doi:10.1089/1547328042417336
Dobaczewski M, Bujak M, Li N et al (2010) Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ Res 107:418–428. doi:10.1161/CIRCRESAHA.109.216101
Dobaczewski M, Chen W, Frangogiannis NG (2011) Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol 51:600–606. doi:10.1016/j.yjmcc.2010.10.033
Doyle AJ, Doyle JJ, Bessling SL et al (2012) Mutations in the TGF-β repressor SKI cause Shprintzen-Goldberg syndrome with aortic aneurysm. Nat Genet. doi:10.1038/ng.2421
Dupuis-Girod S, Ginon I, Saurin J-C et al (2012) Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 307:948–955. doi:10.1001/jama.2012.250
Ellmers LJ, Scott NJA, Medicherla S et al (2008) Transforming growth factor-β blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after myocardial infarction. Endocrinology 149:5828–5834. doi:10.1210/en.2008-0165
Feng X-H, Derynck R (2005) Specificity and versatility in TGF-β signaling through Smads. Annu Rev Cell Dev Biol 21:659–693. doi:10.1146/annurev.cellbio.21.022404.142018
Frantz S, Hu K, Adamek A et al (2008) Transforming growth factor β inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol 103:485–492. doi:10.1007/s00395-008-0739-7
Frid MG, Kale VA, Stenmark KR (2002) Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ Res 90:1189–1196. doi:10.1161/01.RES.0000021432.70309.28
Frostegård J, Ulfgren A-K, Nyberg P et al (1999) Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145:33–43. doi:10.1016/S0021-9150(99)00011-8
Frutkin AD, Otsuka G, Stempien-Otero A et al (2009) TGF-β1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 29:1251–1257. doi:10.1161/ATVBAHA.109.186593
Gallione CJ, Richards JA, Letteboer TGW et al (2006) SMAD4 mutations found in unselected HHT patients. J Med Genet 43:793–797. doi:10.1136/jmg.2006.041517
Ghosh AK, Vaughan DE (2012) PAI-1 in tissue fibrosis. J Cell Physiol 227:493–507. doi:10.1002/jcp.22783
Ghosh AK, Bradham WS, Gleaves LA et al (2010) Genetic deficiency of plasminogen activator inhibitor-1 promotes cardiac fibrosis in aged mice: involvement of constitutive transforming growth factor-β signaling and endothelial-to-mesenchymal transition. Circulation 122:1200–1209. doi:10.1161/CIRCULATIONAHA.110.955245
Gojova A, Brun V, Esposito B et al (2003) Specific abrogation of transforming growth factor-β signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood 102:4052–4058. doi:10.1182/blood-2003-05-1729
Goumans MJ, Mummery C (2000) Functional analysis of the TGF-β receptor/Smad pathway through gene ablation in mice. Int J Dev Biol 44:253–265
Goumans M-J, Valdimarsdottir G, Itoh S et al (2002) Balancing the activation state of the endothelium via two distinct TGF-β type I receptors. EMBO J 21:1743–1753. doi:10.1093/emboj/21.7.1743
Goumans M-J, Valdimarsdottir G, Itoh S et al (2003) Activin receptor-like kinase (ALK)1 Is an antagonistic mediator of lateral TGF-β/ALK5 signaling. Mol Cell 12:817–828. doi:10.1016/S1097-2765(03)00386-1
Goumans M-J, van Zonneveld AJ, ten Dijke P (2008) Transforming growth factor β-induced endothelial-to-mesenchymal transition: a switch to cardiac fibrosis? Trends Cardiovasc Med 18:293–298. doi:10.1016/j.tcm.2009.01.001
Grainger DJ (2004) Transforming growth factor β and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 24:399–404. doi:10.1161/01.ATV.0000114567.76772.33
Grainger DJ, Kemp PR, Metcalfe JC et al (1995) The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat Med 1:74–79. doi:10.1038/nm0195-74
Habashi JP, Judge DP, Holm TM et al (2006) Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312:117–121. doi:10.1126/science.1124287
Hawinkels LJAC, Kuiper P, Wiercinska E et al (2010) Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res 70:4141–4150. doi:10.1158/0008-5472.CAN-09-4466
Herder C, Peeters W, Zierer A et al (2012) TGF-β1 content in atherosclerotic plaques, TGF-β1 serum concentrations and incident coronary events. Eur J Clin Invest 42:329–337. doi:10.1111/j.1365-2362.2011.02587.x
Hering S, Jost C, Schulz H et al (2002) Circulating transforming growth factor β1 (TGF-β1) is elevated by extensive exercise. Eur J Appl Physiol 86:406–410. doi:10.1007/s00421-001-0537-5
Hinton RB, Adelman-Brown J, Witt S et al (2010) Elastin haploinsufficiency results in progressive aortic valve malformation and latent valve disease in a mouse model. Circ Res 107:549–557. doi:10.1161/CIRCRESAHA.110.221358
Holm TM, Habashi JP, Doyle JJ et al (2011) Noncanonical TGF-β signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 332:358–361. doi:10.1126/science.1192149
Horbelt D, Guo G, Robinson PN, Knaus P (2010) Quantitative analysis of TGFBR2 mutations in Marfan-syndrome-related disorders suggests a correlation between phenotypic severity and Smad signaling activity. J Cell Sci 123:4340–4350. doi:10.1242/jcs.074773
Huang S, Tang B, Usoskin D et al (2002) Conditional knockout of the Smad1 gene. Genesis 32:76–79. doi:10.1002/gene.10059
Ikeuchi M, Tsutsui H, Shiomi T et al (2004) Inhibition of TGF-β signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res 64:526–535. doi:10.1016/j.cardiores.2004.07.017
Ishisaki A, Hayashi H, Li A-J, Imamura T (2003) Human umbilical vein endothelium-derived cells retain potential to differentiate into smooth muscle-like cells. J Biol Chem 278:1303–1309. doi:10.1074/jbc.M207329200
Itoh S, ten Dijke P (2007) Negative regulation of TGF-β receptor/Smad signal transduction. Curr Opin Cell Biol 19:176–184. doi:10.1016/j.ceb.2007.02.015
Jerkic M, Rodríguez-Barbero A, Prieto M et al (2006) Reduced angiogenic responses in adult Endoglin heterozygous mice. Cardiovasc Res 69:845–854. doi:10.1016/j.cardiores.2005.11.020
Johnson DW, Berg JN, Baldwin MA et al (1996) Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13:189–195. doi:10.1038/ng0696-189
Judge DP, Rouf R, Habashi J, Dietz HC (2011) Mitral valve disease in Marfan syndrome and related disorders. J Cardiovasc Transl Res 4:741–747. doi:10.1007/s12265-011-9314-y
Kaartinen V, Voncken JW, Shuler C et al (1995) Abnormal lung development and cleft palate in mice lacking TGF-β 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 11:415–421. doi:10.1038/ng1295-415
Kalinina N, Agrotis A, Antropova Y et al (2004) Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 24:2320–2325. doi:10.1161/01.ATV.0000145573.36113.8a
Kallapur S, Ormsby I, Doetschman T (1999) Strain dependency of TGF-β1 function during embryogenesis. Mol Reprod Dev 52:341–349. doi:10.1002/(SICI)1098-2795(199904)52:4<341::AID-MRD2>3.0.CO;2-N
Kano MR, Bae Y, Iwata C et al (2007) Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc Natl Acad Sci USA 104:3460–3465. doi:10.1073/pnas.0611660104
Kapur NK, Wilson S, Yunis AA et al (2012) Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure. Circulation 125:2728–2738. doi:10.1161/CIRCULATIONAHA.111.080002
Kirkbride KC, Ray BN, Blobe GC (2005) Cell-surface co-receptors: emerging roles in signaling and human disease. Trends Biochem Sci 30:611–621. doi:10.1016/j.tibs.2005.09.003
Kokudo T, Suzuki Y, Yoshimatsu Y et al (2008) Snail is required for TGF-β-induced endothelial-mesenchymal transition of embryonic stem cell-derived endothelial cells. J Cell Sci 121:3317–3324. doi:10.1242/jcs.028282
Kruithof BPT, Duim SN, Moerkamp AT, Goumans M-J (2012) TGF-β and BMP signaling in cardiac cushion formation: lessons from mice and chicken. Differentiation 84:89–102. doi:10.1016/j.diff.2012.04.003
Kulkarni AB, Huh CG, Becker D et al (1993) Transforming growth factor β 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA 90:770–774
Kuwahara F, Kai H, Tokuda K et al (2002) Transforming growth factor-β function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106:130–135. doi:10.1161/01.CIR.0000020689.12472.E0
Kyndt F, Gueffet J-P, Probst V et al (2007) Mutations in the gene encoding filamin A as a cause for familial cardiac valvular dystrophy. Circulation 115:40–49. doi:10.1161/CIRCULATIONAHA.106.622621
Lamouille S, Mallet C, Feige J-J, Bailly S (2002) Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 100:4495–4501. doi:10.1182/blood.V100.13.4495
Lan Y, Liu B, Yao H et al (2007) Essential role of endothelial Smad4 in vascular remodeling and integrity. Mol Cell Biol 27:7683–7692. doi:10.1128/MCB.00577-07
Larsson J, Goumans MJ, Sjöstrand LJ et al (2001) Abnormal angiogenesis but intact hematopoietic potential in TGF-β type I receptor-deficient mice. EMBO J 20:1663–1673. doi:10.1093/emboj/20.7.1663
Lastres P (1996) Endoglin modulates cellular responses to TGF-β 1. J Cell Biol 133:1109–1121. doi:10.1083/jcb.133.5.1109
Leask A (2010) Potential therapeutic targets for cardiac fibrosis: TGF-β, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 106:1675–1680. doi:10.1161/CIRCRESAHA.110.217737
Lebrin F, Goumans M-J, Jonker L et al (2004) Endoglin promotes endothelial cell proliferation and TGF-β/ALK1 signal transduction. EMBO J 23:4018–4028. doi:10.1038/sj.emboj.7600386
Lebrin F, Srun S, Raymond K et al (2010) Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 16:420–428. doi:10.1038/nm.2131
Leong KG, Niessen K, Kulic I et al (2007) Jagged1-mediated notch activation induces epithelial-to-mesenchymal transition through slug-induced repression of E-cadherin. J Exp Med 204:2935–2948. doi:10.1084/jem.20071082
Letterio J, Geiser A, Kulkarni A et al (1994) Maternal rescue of transforming growth factor-β 1 null mice. Science 264:1936–1938. doi:10.1126/science.8009224
Levine RJ, Lam C, Qian C et al (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355:992–1005. doi:10.1056/NEJMoa055352
Li DY (1999) Defective angiogenesis in mice lacking endoglin. Science 284:1534–1537. doi:10.1126/science.284.5419.1534
Li Z, Jimenez SA (2011) Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro. Arthritis Rheum 63:2473–2483. doi:10.1002/art.30317
Li RK, Li G, Mickle DA et al (1997) Overexpression of transforming growth factor-β1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation 96:874–881. doi:10.1161/01.CIR.96.3.874
Li C, Guo B, Wilson PB et al (2000a) Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer 89:122–126. doi:10.1002/(SICI)1097-0215(20000320)89:2<122::AID-IJC4>3.0.CO;2-M
Li C, Bethell H, Wilson P et al (2000b) The significance of CD105, TGF-β and CD105/TGF-β complexes in coronary artery disease. Atherosclerosis 152:249–256. doi:10.1016/S0021-9150(99)00476-1
Li C, Issa R, Kumar P et al (2003) CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci 116:2677–2685. doi:10.1242/jcs.00470
Libby P, Ridker PM, Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473:317–325. doi:10.1038/nature10146
Lievens D, Habets KL, Robertson A-K et al (2012) Abrogated transforming growth factor β receptor II (TGFβRII) signalling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis. Eur Heart J. doi:10.1093/eurheartj/ehs106
Lindsay ME, Schepers D, Bolar NA et al (2012) Loss-of-function mutations in TGF-β2 cause a syndromic presentation of thoracic aortic aneurysm. Nat Genet 44:922–927. doi:10.1038/ng.2349
Liu Z, Kobayashi K, van Dinther M et al (2009) VEGF and inhibitors of TGF-β type-I receptor kinase synergistically promote blood-vessel formation by inducing α5-integrin expression. J Cell Sci 122:3294–3302. doi:10.1242/jcs.048942
Liu Z, Afink GB, ten Dijke P (2012) Soluble fms-like tyrosine kinase 1 and soluble endoglin are elevated circulating anti-angiogenic factors in pre-eclampsia. Pregnancy Hypertens Int J Wom Cardiovasc Health 2:358–367. doi:10.1016/j.preghy.2012.06.003
Loeys BL, Chen J, Neptune ER et al (2005) A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet 37:275–281. doi:10.1038/ng1511
Loeys BL, Schwarze U, Holm T et al (2006) Aneurysm syndromes caused by mutations in the TGF-β receptor. N Engl J Med 355:788–798. doi:10.1056/NEJMoa055695
Long L, Crosby A, Yang X et al (2009) Altered bone morphogenetic protein and transforming growth factor-β signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 119:566–576. doi:10.1161/CIRCULATIONAHA.108.821504
Lopez D, Niu G, Huber P, Carter WB (2009) Tumor-induced upregulation of twist, snail, and slug represses the activity of the human VE-cadherin promoter. Arch Biochem Biophys 482:77–82. doi:10.1016/j.abb.2008.11.016
Lucas JA, Zhang Y, Li P et al (2010) Inhibition of transforming growth factor-β signaling induces left ventricular dilation and dysfunction in the pressure-overloaded heart. Am J Physiol Heart Circ Physiol 298:H424–H432. doi:10.1152/ajpheart.00529.2009
Lutgens E (2002) Transforming growth factor-β mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 22:975–982. doi:10.1161/01.ATV.0000019729.39500.2F
Mallat Z, Gojova A, Marchiol-Fournigault C et al (2001) Inhibition of transforming growth factor-β signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 89:930–934. doi:10.1161/hh2201.099415
Mallet C, Vittet D, Feige J-J, Bailly S (2006) TGF-β1 induces vasculogenesis and inhibits angiogenic sprouting in an embryonic stem cell differentiation model: respective contribution of ALK1 and ALK5. Stem Cells 24:2420–2427. doi:10.1634/stemcells.2005-0494
Martin J, Kelly DJ, Mifsud SA et al (2005) Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-β. Cardiovasc Res 65:694–701. doi:10.1016/j.cardiores.2004.10.041
Massagué J (1998) TGF-β signal transduction. Annu Rev Biochem 67:753–791. doi:10.1146/annurev.biochem.67.1.753
McAllister KA, Grogg KM, Johnson DW et al (1994) Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8:345–351. doi:10.1038/ng1294-345
Medici D, Shore EM, Lounev VY et al (2010) Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med 16:1400–1406. doi:10.1038/nm.2252
Milewicz DM, Michael K, Fisher N et al (1996) Fibrillin-1 (FBN1) mutations in patients with thoracic aortic aneurysms. Circulation 94:2708–2711. doi:10.1161/01.CIR.94.11.2708
Möberg K, De Nobele S, Devos D et al (2012) The Ghent Marfan Trial—a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with β-blockers. Int J Cardiol 157:354–358. doi:10.1016/j.ijcard.2010.12.070
Molin DGM, Bartram U, Van der Heiden K et al (2003) Expression patterns of TGF-β1-3 associate with myocardialisation of the outflow tract and the development of the epicardium and the fibrous heart skeleton. Dev Dyn 227:431–444. doi:10.1002/dvdy.10314
Moustakas A, Heldin C-H (2005) Non-Smad TGF-β signals. J Cell Sci 118:3573–3584. doi:10.1242/jcs.02554
Moustakas A, Heldin C-H (2009) The regulation of TGF-β signal transduction. Development 136:3699–3714. doi:10.1242/dev.030338
Neptune ER, Frischmeyer PA, Arking DE et al (2003) Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33:407–411. doi:10.1038/ng1116
Noseda M, McLean G, Niessen K et al (2004) Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformation. Circ Res 94:910–917. doi:10.1161/01.RES.0000124300.76171.C9
Obreo J, Díez-Marques L, Lamas S et al (2004) Endoglin expression regulates basal and TGF-β1-induced extracellular matrix synthesis in cultured L6E9 myoblasts. Cell Physiol Biochem 14:301–310. doi:10.1159/000080340
Oh SP, Seki T, Goss KA et al (2000) Activin receptor-like kinase 1 modulates transforming growth factor-β 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci 97:2626–2631. doi:10.1073/pnas.97.6.2626
Okada H, Takemura G, Kosai K et al (2005) Postinfarction gene therapy against transforming growth factor-β signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure. Circulation 111:2430–2437. doi:10.1161/01.CIR.0000165066.71481.8E
Owens GK (1995) Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 75:487–517
Pannu H, Fadulu VT, Chang J et al (2005) Mutations in transforming growth factor-β receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation 112:513–520. doi:10.1161/CIRCULATIONAHA.105.537340
Panutsopulos D, Papalambros E, Sigala F et al (2005) Protein and mRNA expression levels of VEGF-A and TGF-β1 in different types of human coronary atherosclerotic lesions. Int J Mol Med 15:603–610
Park SO, Lee YJ, Seki T et al (2008) ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 111:633–642. doi:10.1182/blood-2007-08-107359
Park SO, Wankhede M, Lee YJ et al (2009) Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest 119:3487–3496. doi:10.1172/JCI39482
Pauschinger M, Knopf D, Petschauer S et al (1999) Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. Circulation 99:2750–2756. doi:10.1161/01.CIR.99.21.2750
Potts JD, Dagle JM, Walder JA et al (1991) Epithelial-mesenchymal transformation of embryonic cardiac endothelial cells is inhibited by a modified antisense oligodeoxynucleotide to transforming growth factor β 3. Proc Natl Acad Sci USA 88:1516–1520
Ramirez F, Dietz HC (2007) Marfan syndrome: from molecular pathogenesis to clinical treatment. Curr Opin Genet Dev 17:252–258. doi:10.1016/j.gde.2007.04.006
Reed DM, Foldes G, Harding SE, Mitchell JA (2012) Stem cell derived endothelial cells for cardiovascular disease; a therapeutic perspective. Br J Clin Pharmacol. doi:10.1111/j.1365-2125.2012.04361.x
Regalado ES, Guo D-C, Villamizar C et al (2011) Exome sequencing identifies SMAD3 mutations as a cause of familial thoracic aortic aneurysm and dissection with intracranial and other arterial aneurysms. Circ Res 109:680–686. doi:10.1161/CIRCRESAHA.111.248161
Robertson A-KL, Rudling M, Zhou X et al (2003) Disruption of TGF-β signaling in T cells accelerates atherosclerosis. J Clin Invest 112:1342–1350. doi:10.1172/JCI18607
Roman BL, Pham VN, Lawson ND et al (2002) Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels. Development 129:3009–3019
Rosenkranz S, Flesch M, Amann K et al (2002) Alterations of β-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-β(1). Am J Physiol Heart Circ Physiol 283:H1253–H1262. doi:10.1152/ajpheart.00578.2001
Rudini N, Felici A, Giampietro C et al (2008) VE-cadherin is a critical endothelial regulator of TGF-β signalling. EMBO J 27:993–1004. doi:10.1038/emboj.2008.46
Sanford LP, Ormsby I, Gittenberger-de Groot AC et al (1997) TGF-β2 knockout mice have multiple developmental defects that are non-overlapping with other TGF-β knockout phenotypes. Development 124:2659–2670
Seki T, Hong K-H, Oh SP (2006) Nonoverlapping expression patterns of ALK1 and ALK5 reveal distinct roles of each receptor in vascular development. Lab Invest 86:116–129. doi:10.1038/labinvest.3700376
Shull MM, Ormsby I, Kier AB et al (1992) Targeted disruption of the mouse transforming growth factor-β 1 gene results in multifocal inflammatory disease. Nature 359:693–699. doi:10.1038/359693a0
Silver MA, Pick R, Brilla CG et al (1990) Reactive and reparative fibrillar collagen remodelling in the hypertrophied rat left ventricle: two experimental models of myocardial fibrosis. Cardiovasc Res 24:741–747. doi:10.1093/cvr/24.9.741
Souders CA, Bowers SLK, Baudino TA (2009) Cardiac fibroblast: the renaissance cell. Circ Res 105:1164–1176. doi:10.1161/CIRCRESAHA.109.209809
Sridurongrit S, Larsson J, Schwartz R et al (2008) Signaling via the TGF-β type I receptor Alk5 in heart development. Dev Biol 322:208–218. doi:10.1016/j.ydbio.2008.07.038
Stenvers KL, Tursky ML, Harder KW et al (2003) Heart and liver defects and reduced transforming growth factor 2 sensitivity in transforming growth factor type III receptor-deficient embryos. Mol Cell Biol 23:4371–4385. doi:10.1128/MCB.23.12.4371-4385.2003
ten Dijke P, Arthur HM (2007) Extracellular control of TGF-β signalling in vascular development and disease. Nat Rev Mol Cell Biol 8:857–869. doi:10.1038/nrm2262
ten Dijke P, Goumans M-J, Pardali E (2008) Endoglin in angiogenesis and vascular diseases. Angiogenesis 11:79–89. doi:10.1007/s10456-008-9101-9
Thiery JP, Acloque H, Huang RYJ, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139:871–890. doi:10.1016/j.cell.2009.11.007
Tian H, Mythreye K, Golzio C et al (2012) Endoglin mediates fibronectin/α5β1 integrin and TGF-β pathway crosstalk in endothelial cells. EMBO J 31:3885–3900. doi:10.1038/emboj.2012.246
Timmerman LA, Grego-Bessa J, Raya A et al (2004) Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev 18:99–115. doi:10.1101/gad.276304
Toma I, McCaffrey TA (2012) Transforming growth factor-β and atherosclerosis: interwoven atherogenic and atheroprotective aspects. Cell Tissue Res 347:155–175. doi:10.1007/s00441-011-1189-3
Tran-Fadulu V, Pannu H, Kim DH et al (2009) Analysis of multigenerational families with thoracic aortic aneurysms and dissections due to TGFBR1 or TGFBR2 mutations. J Med Genet 46:607–613. doi:10.1136/jmg.2008.062844
Urness LD, Sorensen LK, Li DY (2000) Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 26:328–331. doi:10.1038/81634
Valdimarsdottir G, Goumans M-J, Rosendahl A et al (2002) Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation 106:2263–2270. doi:10.1161/01.CIR.0000033830.36431.46
van de Laar IMBH, van der Linde D, Oei EHG et al (2012) Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome. J Med Genet 49:47–57. doi:10.1136/jmedgenet-2011-100382
van Meeteren LA, ten Dijke P (2012) Regulation of endothelial cell plasticity by TGF-β. Cell Tissue Res 347:177–186. doi:10.1007/s00441-011-1222-6
van Meeteren LA, Goumans M-J, ten Dijke P (2011) TGF-β receptor signaling pathways in angiogenesis; emerging targets for anti-angiogenesis therapy. Curr Pharm Biotechnol 12:2108–2120. doi:BSP/CPB/E-Pub/000240-12-16 [pii]
van Meeteren LA, Thorikay M, Bergqvist S et al (2012) Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. J Biol Chem 287:18551–18561. doi:10.1074/jbc.M111.338103
Velasco-Loyden G, Arribas J, López-Casillas F (2004) The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1. J Biol Chem 279:7721–7733. doi:10.1074/jbc.M306499200
Villarreal FJ, Dillmann WH (1992) Cardiac hypertrophy-induced changes in mRNA levels for TGF-β 1, fibronectin, and collagen. Am J Physiol 262:H1861–H1866
Wang X (1997) Circulating transforming growth factor β1 and coronary artery disease. Cardiovasc Res 34:404–410. doi:10.1016/S0008-6363(97)00033-3
Wang X-F, Lin HY, Ng-Eaton E et al (1991) Expression cloning and characterization of the TGF-β type III receptor. Cell 67:797–805. doi:10.1016/0092-8674(91)90074-9
Watabe T, Nishihara A, Mishima K et al (2003) TGF-β receptor kinase inhibitor enhances growth and integrity of embryonic stem cell-derived endothelial cells. J Cell Biol 163:1303–1311. doi:10.1083/jcb.200305147
Westermann D, Van Linthout S, Dhayat S et al (2007) Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes 56:1834–1841. doi:10.2337/db06-1662
Wong SH, Hamel L, Chevalier S, Philip A (2000) Endoglin expression on human microvascular endothelial cells. Eur J Biochem 267:5550–5560. doi:10.1046/j.1432-1327.2000.01621.x
Yang X, Castilla LH, Xu X et al (1999) Angiogenesis defects and mesenchymal apoptosis in mice lacking SMAD5. Development 126:1571–1580
Zeisberg EM, Potenta S, Xie L et al (2007a) Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 67:10123–10128. doi:10.1158/0008-5472.CAN-07-3127
Zeisberg EM, Tarnavski O, Zeisberg M et al (2007b) Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13:952–961. doi:10.1038/nm1613
Zhang YE (2009) Non-Smad pathways in TGF-β signaling. Cell Res 19:128–139. doi:10.1038/cr.2008.328
Zhang D, Gaussin V, Taffet GE et al (2000) TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 6:556–563. doi:10.1038/75037
Acknowledgments
Research on TGF-β in vascular disorders in our laboratory is supported by grants from Dutch Cancer Society, Netherlands organization for scientific research, KNAW, and the LeDucq foundation.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer
About this chapter
Cite this chapter
van Meeteren, L.A., Goumans, MJ., Dijke, P.t. (2013). TGF-β and Cardiovascular Disorders. In: Moustakas, A., Miyazawa, K. (eds) TGF-β in Human Disease. Springer, Tokyo. https://doi.org/10.1007/978-4-431-54409-8_13
Download citation
DOI: https://doi.org/10.1007/978-4-431-54409-8_13
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-54408-1
Online ISBN: 978-4-431-54409-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)